Immunogenic Hybrid Nanovesicles of Liposomes and Tumor-Derived Nanovesicles for Cancer Immunochemotherapy

Exploring a rational delivery system of integrating chemotherapy with immunotherapy to broaden benefits of cancer immunochemotherapy is still under challenge. Herein, we developed doxorubicin (DOX)-loaded biomimetic hybrid nanovesicles (DOX@LINV) via fusing artificial liposomes (LIPs) with tumor-der...

Full description

Saved in:
Bibliographic Details
Published inACS nano Vol. 15; no. 2; pp. 3123 - 3138
Main Authors Hu, Mei, Zhang, Jiao, Kong, Li, Yu, Yulin, Hu, Qian, Yang, Ting, Wang, Yi, Tu, Kun, Qiao, Qi, Qin, Xianya, Zhang, Zhiping
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 23.02.2021
Subjects
Animals
Cell Line, Tumor
Doxorubicin - pharmacology
Drug Delivery Systems
Immunotherapy
Liposomes
Mice
Mice, Inbred BALB C
Neoplasms
hybrid nanovesicles
liposomes
tumor-derived nanovesicles
immunogenic cell death
immunochemotherapy
Online AccessGet full text

Cover

Abstract Exploring a rational delivery system of integrating chemotherapy with immunotherapy to broaden benefits of cancer immunochemotherapy is still under challenge. Herein, we developed doxorubicin (DOX)-loaded biomimetic hybrid nanovesicles (DOX@LINV) via fusing artificial liposomes (LIPs) with tumor-derived nanovesicles (TNVs) for combinational immunochemotherapy. DOX@LINV with a homologous targeting ability could deliver DOX to tumor tissue and elicit an effective immunogenic cell death response to improve the immunogenicity of a tumor. Meanwhile, the preserved tumor antigens and endogenous danger signals in DOX@LINV activated dendritic cells and induced a subsequent antigen-specific T cell immune response. DOX@LINV displayed a specific antitumor effect on murine melanoma, Lewis lung cancer, and 4T1 breast cancer based on the infiltration of effector immune cells and improvement of the immunosuppressive tumor microenvironment. Furthermore, the combination of DOX@LINV with immune checkpoint inhibitor amplified antitumor efficacy with 33.3% of the mice being tumor-free. Therefore, the hybrid LINV is a promising drug delivery platform with a boosted antitumor immune response for effective immunochemotherapy.
AbstractList Exploring a rational delivery system of integrating chemotherapy with immunotherapy to broaden benefits of cancer immunochemotherapy is still under challenge. Herein, we developed doxorubicin (DOX)-loaded biomimetic hybrid nanovesicles (DOX@LINV) via fusing artificial liposomes (LIPs) with tumor-derived nanovesicles (TNVs) for combinational immunochemotherapy. DOX@LINV with a homologous targeting ability could deliver DOX to tumor tissue and elicit an effective immunogenic cell death response to improve the immunogenicity of a tumor. Meanwhile, the preserved tumor antigens and endogenous danger signals in DOX@LINV activated dendritic cells and induced a subsequent antigen-specific T cell immune response. DOX@LINV displayed a specific antitumor effect on murine melanoma, Lewis lung cancer, and 4T1 breast cancer based on the infiltration of effector immune cells and improvement of the immunosuppressive tumor microenvironment. Furthermore, the combination of DOX@LINV with immune checkpoint inhibitor amplified antitumor efficacy with 33.3% of the mice being tumor-free. Therefore, the hybrid LINV is a promising drug delivery platform with a boosted antitumor immune response for effective immunochemotherapy.
Exploring a rational delivery system of integrating chemotherapy with immunotherapy to broaden benefits of cancer immunochemotherapy is still under challenge. Herein, we developed doxorubicin (DOX)-loaded biomimetic hybrid nanovesicles (DOX@LINV) fusing artificial liposomes (LIPs) with tumor-derived nanovesicles (TNVs) for combinational immunochemotherapy. DOX@LINV with a homologous targeting ability could deliver DOX to tumor tissue and elicit an effective immunogenic cell death response to improve the immunogenicity of a tumor. Meanwhile, the preserved tumor antigens and endogenous danger signals in DOX@LINV activated dendritic cells and induced a subsequent antigen-specific T cell immune response. DOX@LINV displayed a specific antitumor effect on murine melanoma, Lewis lung cancer, and 4T1 breast cancer based on the infiltration of effector immune cells and improvement of the immunosuppressive tumor microenvironment. Furthermore, the combination of DOX@LINV with immune checkpoint inhibitor amplified antitumor efficacy with 33.3% of the mice being tumor-free. Therefore, the hybrid LINV is a promising drug delivery platform with a boosted antitumor immune response for effective immunochemotherapy.
Author Wang, Yi
Tu, Kun
Hu, Mei
Zhang, Jiao
Qiao, Qi
Hu, Qian
Yang, Ting
Yu, Yulin
Kong, Li
Qin, Xianya
Zhang, Zhiping
AuthorAffiliation Tongji School of Pharmacy
Hubei Engineering Research Centre for Novel Drug Delivery System
National Engineering Research Center for Nanomedicine
AuthorAffiliation_xml – name: Tongji School of Pharmacy
– name: National Engineering Research Center for Nanomedicine
– name: Hubei Engineering Research Centre for Novel Drug Delivery System
Author_xml – sequence: 1
  givenname: Mei
  surname: Hu
  fullname: Hu, Mei
  organization: Tongji School of Pharmacy
– sequence: 2
  givenname: Jiao
  surname: Zhang
  fullname: Zhang, Jiao
  organization: Tongji School of Pharmacy
– sequence: 3
  givenname: Li
  surname: Kong
  fullname: Kong, Li
  organization: Tongji School of Pharmacy
– sequence: 4
  givenname: Yulin
  surname: Yu
  fullname: Yu, Yulin
  organization: Tongji School of Pharmacy
– sequence: 5
  givenname: Qian
  surname: Hu
  fullname: Hu, Qian
  organization: Tongji School of Pharmacy
– sequence: 6
  givenname: Ting
  surname: Yang
  fullname: Yang, Ting
  organization: Tongji School of Pharmacy
– sequence: 7
  givenname: Yi
  surname: Wang
  fullname: Wang, Yi
  organization: Tongji School of Pharmacy
– sequence: 8
  givenname: Kun
  surname: Tu
  fullname: Tu, Kun
  organization: Tongji School of Pharmacy
– sequence: 9
  givenname: Qi
  surname: Qiao
  fullname: Qiao, Qi
  organization: Tongji School of Pharmacy
– sequence: 10
  givenname: Xianya
  surname: Qin
  fullname: Qin, Xianya
  organization: Tongji School of Pharmacy
– sequence: 11
  givenname: Zhiping
  orcidid: 0000-0002-9235-5321
  surname: Zhang
  fullname: Zhang, Zhiping
  email: zhipingzhang@mail.hust.edu.cn
  organization: Hubei Engineering Research Centre for Novel Drug Delivery System
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33470095$$D View this record in MEDLINE/PubMed
BookMark eNp1kM9LwzAUx4NM3A89e5MeBemWNGnTHmX-2GDoZYK3kqavrqNJarIO9t8bafUgeHrvwef7gfedopE2GhC6JnhOcEQWQjottJljibMkJWdoQjKahDhN3ke_e0zGaOrcHuOYpzy5QGNKGcc4iyeoXivVafMBupbB6lTYugxevPEIrpYNuMBUwaZujTPKH0KXwbZTxoYPYOsj_GErY4Ol0BJs0GvlDpQ57MCK9nSJzivROLga5gy9PT1ul6tw8_q8Xt5vQkEpPYRxDEnFSEQgBk6ymFIsaFVWUFCGsSAQVYxziJMEiojLkpI0Y0BYGdHChzI6Q7e9t7XmswN3yFXtJDSN0GA6l0eMZywiHFOPLnpUWuOchSpvba2EPeUE59_95kO_-dCvT9wM8q5QUP7yP4V64K4HfDLfm85q_-u_ui80r4l8
CitedBy_id crossref_primary_10_3390_ijms25042165
crossref_primary_10_1039_D3FO05441A
crossref_primary_10_1002_sstr_202400028
crossref_primary_10_1016_j_mtbio_2023_100625
crossref_primary_10_1016_j_bioactmat_2022_08_010
crossref_primary_10_1016_j_nantod_2024_102321
crossref_primary_10_1002_smtd_202200925
crossref_primary_10_3389_fbioe_2023_1121887
crossref_primary_10_1016_j_jconrel_2022_12_027
crossref_primary_10_1016_j_cclet_2024_109578
crossref_primary_10_1097_CM9_0000000000002525
crossref_primary_10_1039_D1CC04604G
crossref_primary_10_1016_j_jconrel_2023_08_002
crossref_primary_10_1021_acsnano_2c11159
crossref_primary_10_1039_D3CS00602F
crossref_primary_10_1016_j_bcp_2024_116220
crossref_primary_10_1039_D2CS00437B
crossref_primary_10_1039_D4BM00159A
crossref_primary_10_1002_adfm_202107540
crossref_primary_10_1016_j_jconrel_2023_10_022
crossref_primary_10_1186_s12951_024_02345_3
crossref_primary_10_1038_s41401_022_00976_6
crossref_primary_10_1016_j_cej_2023_146276
crossref_primary_10_1016_j_biomaterials_2022_121518
crossref_primary_10_3389_fbioe_2022_850366
crossref_primary_10_1016_j_addr_2021_113905
crossref_primary_10_1039_D3NR05195A
crossref_primary_10_1002_smll_202204689
crossref_primary_10_3390_pharmaceutics14112326
crossref_primary_10_1016_j_addr_2021_113909
crossref_primary_10_1021_acsnano_1c09635
crossref_primary_10_1186_s12943_023_01797_9
crossref_primary_10_1002_btm2_10601
crossref_primary_10_1016_j_ejpb_2024_114259
crossref_primary_10_1039_D3BM01628E
crossref_primary_10_1016_j_cclet_2021_10_074
crossref_primary_10_1016_j_cclet_2024_109942
crossref_primary_10_1002_adhm_202202903
crossref_primary_10_1021_acsnano_3c10623
crossref_primary_10_1021_acs_analchem_3c04306
crossref_primary_10_1021_acsnano_3c09848
crossref_primary_10_1016_j_apsb_2022_09_004
crossref_primary_10_1002_adma_202402322
crossref_primary_10_1016_j_ijbiomac_2023_123159
crossref_primary_10_2147_IJN_S455021
crossref_primary_10_1016_j_mtbio_2023_100751
crossref_primary_10_3390_nano14070639
crossref_primary_10_3390_nano13202751
crossref_primary_10_1063_5_0137026
crossref_primary_10_1021_jacs_1c03071
crossref_primary_10_1016_j_canlet_2022_215934
crossref_primary_10_1002_smll_202205166
crossref_primary_10_1002_smsc_202300084
crossref_primary_10_1088_1758_5090_ac8621
crossref_primary_10_1021_acs_molpharmaceut_3c00376
crossref_primary_10_1186_s12951_021_01158_y
crossref_primary_10_1002_adma_202400196
crossref_primary_10_1039_D3TB02149A
crossref_primary_10_1021_acsnano_3c13056
crossref_primary_10_1002_advs_202204932
crossref_primary_10_2174_1389201024666230821090222
crossref_primary_10_1016_j_canlet_2023_216397
crossref_primary_10_2147_IJN_S388075
crossref_primary_10_2174_1567201820666230504120841
crossref_primary_10_1016_j_addr_2022_114324
crossref_primary_10_1021_acsnano_3c10212
crossref_primary_10_1186_s12951_021_01085_y
crossref_primary_10_1021_acsnano_3c03456
crossref_primary_10_1016_j_colsurfb_2023_113704
crossref_primary_10_1016_j_cej_2021_133747
crossref_primary_10_2174_1389557523666230203145645
crossref_primary_10_1021_acsbiomaterials_3c00364
crossref_primary_10_1021_acsnano_2c06357
crossref_primary_10_1021_acsami_4c04604
crossref_primary_10_1021_acsabm_1c00804
crossref_primary_10_2147_IJN_S441135
crossref_primary_10_1016_j_jcis_2023_05_114
crossref_primary_10_1016_j_semcancer_2021_11_005
crossref_primary_10_1186_s12951_022_01270_7
crossref_primary_10_3389_fbioe_2022_887548
crossref_primary_10_3390_pharmaceutics16010007
crossref_primary_10_1016_j_jconrel_2024_04_015
crossref_primary_10_1186_s12951_022_01692_3
crossref_primary_10_1186_s12951_023_01766_w
crossref_primary_10_1002_adhm_202202209
crossref_primary_10_3390_biomedicines11082245
crossref_primary_10_3390_ijms22041873
crossref_primary_10_2217_nnm_2023_0332
crossref_primary_10_1080_10717544_2022_2104404
crossref_primary_10_2174_1871520622666220215124434
crossref_primary_10_1002_mabi_202300093
crossref_primary_10_1002_smll_202308639
crossref_primary_10_1016_j_biomaterials_2022_121449
crossref_primary_10_1002_cmdc_202300647
Cites_doi 10.1158/2326-6066.CIR-13-0121
10.1021/acsnano.8b02053
10.1021/nl500618u
10.1021/acs.nanolett.9b02903
10.1016/j.biomaterials.2011.01.067
10.1073/pnas.1500712112
10.3402/jev.v4.30087
10.1021/acsnano.0c00962
10.1016/j.msec.2019.01.066
10.1002/smll.201200217
10.1038/s41467-019-09760-3
10.1016/j.immuni.2015.11.024
10.1021/acs.nanolett.6b02786
10.1038/ncomms12499
10.1021/acsnano.7b00715
10.1126/science.1224922
10.1038/ncomms13443
10.1016/j.actbio.2018.10.029
10.1038/s41467-019-09221-x
10.1111/j.0105-2896.2010.00908.x
10.1016/S0140-6736(16)00561-4
10.1038/nm1216-1502b
10.1021/acs.biomac.7b01176
10.1002/advs.201700611
10.1158/0008-5472.CAN-12-2236
10.1038/nnano.2015.342
10.1016/j.coi.2013.12.005
10.1084/jem.20050915
10.1016/j.biomaterials.2017.05.003
10.1038/85286
10.4049/jimmunol.1002991
10.1038/s41467-018-04703-w
10.1002/ijc.27755
10.1016/S0190-9622(96)90745-8
10.1021/acs.nanolett.7b01193
10.1007/s00018-018-2842-8
10.1038/nature21349
10.1021/nn402232g
10.1007/s12253-015-9913-z
10.1016/j.cell.2016.01.043
10.1016/j.jconrel.2017.08.009
10.1016/j.actbio.2019.05.054
10.1021/acs.nanolett.7b03186
10.1158/1078-0432.CCR-10-3126
10.1038/ncomms2282
10.1038/nature15756
10.1021/acsnano.8b02587
10.1038/nrc3380
10.1038/mt.2008.1
10.1016/j.tibtech.2017.03.004
10.1016/j.coi.2015.12.003
10.1016/j.colsurfb.2014.09.029
10.1021/acsnano.9b08798
10.1038/85438
10.1158/2326-6066.CIR-14-0177
10.1016/j.biomaterials.2016.02.025
10.1016/j.canlet.2008.10.021
10.1016/j.ymthe.2017.04.026
10.1038/nmat4644
ContentType Journal Article
Copyright 2021 American Chemical Society
Copyright_xml – notice: 2021 American Chemical Society
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1021/acsnano.0c09681
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 1936-086X
EndPage 3138
ExternalDocumentID 10_1021_acsnano_0c09681
33470095
i78314485
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID -
23M
53G
55A
5GY
5VS
7~N
AABXI
ABMVS
ABUCX
ACGFS
ACS
AEESW
AENEX
AFEFF
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
CS3
EBS
ED
ED~
F5P
GNL
IH9
IHE
JG
JG~
P2P
RNS
ROL
UI2
VF5
VG9
W1F
XKZ
YZZ
---
.K2
4.4
6J9
AAHBH
ABJNI
ABQRX
ACBEA
ACGFO
ADHLV
AHGAQ
BAANH
CGR
CUPRZ
CUY
CVF
ECM
EIF
GGK
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-a333t-55e6f4121e5e7195330a3fdfeb3400a1e2f477e566eb27cd31894e14d23b21e93
IEDL.DBID ACS
ISSN 1936-0851
IngestDate Fri Aug 16 10:26:45 EDT 2024
Fri Aug 23 02:58:31 EDT 2024
Sat Sep 28 08:26:50 EDT 2024
Thu Feb 25 04:42:15 EST 2021
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords hybrid nanovesicles
liposomes
tumor-derived nanovesicles
immunogenic cell death
immunochemotherapy
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a333t-55e6f4121e5e7195330a3fdfeb3400a1e2f477e566eb27cd31894e14d23b21e93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-9235-5321
PMID 33470095
PQID 2479421703
PQPubID 23479
PageCount 16
ParticipantIDs proquest_miscellaneous_2479421703
crossref_primary_10_1021_acsnano_0c09681
pubmed_primary_33470095
acs_journals_10_1021_acsnano_0c09681
ProviderPackageCode JG~
55A
AABXI
GNL
VF5
XKZ
7~N
VG9
W1F
ACS
AEESW
AFEFF
ABMVS
ABUCX
IH9
AQSVZ
ED~
UI2
PublicationCentury 2000
PublicationDate 20210223
2021-02-23
PublicationDateYYYYMMDD 2021-02-23
PublicationDate_xml – month: 02
  year: 2021
  text: 20210223
  day: 23
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle ACS nano
PublicationTitleAlternate ACS Nano
PublicationYear 2021
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References ref9/cit9
ref45/cit45
ref3/cit3
ref27/cit27
ref56/cit56
ref16/cit16
ref52/cit52
ref23/cit23
ref8/cit8
ref31/cit31
ref59/cit59
ref2/cit2
ref34/cit34
ref37/cit37
ref20/cit20
ref48/cit48
ref60/cit60
ref17/cit17
ref10/cit10
ref35/cit35
ref53/cit53
ref19/cit19
ref21/cit21
ref42/cit42
ref46/cit46
ref49/cit49
ref13/cit13
ref24/cit24
ref38/cit38
ref50/cit50
ref54/cit54
ref6/cit6
ref36/cit36
ref18/cit18
ref11/cit11
ref25/cit25
ref29/cit29
ref32/cit32
ref39/cit39
ref14/cit14
ref57/cit57
ref5/cit5
ref51/cit51
ref43/cit43
ref28/cit28
ref26/cit26
ref55/cit55
ref12/cit12
ref15/cit15
Mendiratta S. K. (ref40/cit40) 2001; 61
ref41/cit41
ref58/cit58
ref22/cit22
ref33/cit33
ref4/cit4
ref30/cit30
ref47/cit47
ref1/cit1
ref44/cit44
ref7/cit7
References_xml – ident: ref52/cit52
  doi: 10.1158/2326-6066.CIR-13-0121
– ident: ref25/cit25
  doi: 10.1021/acsnano.8b02053
– ident: ref37/cit37
  doi: 10.1021/nl500618u
– ident: ref5/cit5
  doi: 10.1021/acs.nanolett.9b02903
– ident: ref60/cit60
  doi: 10.1016/j.biomaterials.2011.01.067
– ident: ref47/cit47
  doi: 10.1073/pnas.1500712112
– ident: ref19/cit19
  doi: 10.3402/jev.v4.30087
– ident: ref42/cit42
  doi: 10.1021/acsnano.0c00962
– ident: ref33/cit33
  doi: 10.1016/j.msec.2019.01.066
– ident: ref36/cit36
  doi: 10.1002/smll.201200217
– ident: ref58/cit58
  doi: 10.1038/s41467-019-09760-3
– ident: ref35/cit35
  doi: 10.1016/j.immuni.2015.11.024
– ident: ref38/cit38
  doi: 10.1021/acs.nanolett.6b02786
– ident: ref6/cit6
  doi: 10.1038/ncomms12499
– ident: ref41/cit41
  doi: 10.1021/acsnano.7b00715
– ident: ref53/cit53
  doi: 10.1126/science.1224922
– ident: ref9/cit9
  doi: 10.1038/ncomms13443
– ident: ref27/cit27
  doi: 10.1016/j.actbio.2018.10.029
– ident: ref10/cit10
  doi: 10.1038/s41467-019-09221-x
– ident: ref50/cit50
  doi: 10.1111/j.0105-2896.2010.00908.x
– ident: ref2/cit2
  doi: 10.1016/S0140-6736(16)00561-4
– ident: ref57/cit57
  doi: 10.1038/nm1216-1502b
– ident: ref29/cit29
  doi: 10.1021/acs.biomac.7b01176
– ident: ref30/cit30
  doi: 10.1002/advs.201700611
– ident: ref46/cit46
  doi: 10.1158/0008-5472.CAN-12-2236
– ident: ref44/cit44
  doi: 10.1038/nnano.2015.342
– ident: ref51/cit51
  doi: 10.1016/j.coi.2013.12.005
– ident: ref59/cit59
  doi: 10.1084/jem.20050915
– ident: ref26/cit26
  doi: 10.1016/j.biomaterials.2017.05.003
– ident: ref49/cit49
  doi: 10.1038/85286
– ident: ref20/cit20
  doi: 10.4049/jimmunol.1002991
– ident: ref7/cit7
  doi: 10.1038/s41467-018-04703-w
– ident: ref48/cit48
  doi: 10.1002/ijc.27755
– ident: ref55/cit55
  doi: 10.1016/S0190-9622(96)90745-8
– ident: ref8/cit8
  doi: 10.1021/acs.nanolett.7b01193
– ident: ref12/cit12
  doi: 10.1007/s00018-018-2842-8
– ident: ref1/cit1
  doi: 10.1038/nature21349
– ident: ref32/cit32
  doi: 10.1021/nn402232g
– ident: ref54/cit54
  doi: 10.1007/s12253-015-9913-z
– ident: ref15/cit15
  doi: 10.1016/j.cell.2016.01.043
– ident: ref45/cit45
  doi: 10.1016/j.jconrel.2017.08.009
– ident: ref24/cit24
  doi: 10.1016/j.actbio.2019.05.054
– ident: ref4/cit4
  doi: 10.1021/acs.nanolett.7b03186
– ident: ref3/cit3
  doi: 10.1158/1078-0432.CCR-10-3126
– ident: ref22/cit22
  doi: 10.1038/ncomms2282
– ident: ref56/cit56
  doi: 10.1038/nature15756
– ident: ref23/cit23
  doi: 10.1021/acsnano.8b02587
– ident: ref43/cit43
  doi: 10.1038/nrc3380
– ident: ref18/cit18
  doi: 10.1038/mt.2008.1
– ident: ref14/cit14
  doi: 10.1016/j.tibtech.2017.03.004
– ident: ref11/cit11
  doi: 10.1016/j.coi.2015.12.003
– ident: ref28/cit28
  doi: 10.1016/j.colsurfb.2014.09.029
– ident: ref39/cit39
  doi: 10.1021/acsnano.9b08798
– ident: ref17/cit17
  doi: 10.1038/85438
– volume: 61
  start-page: 859
  issue: 3
  year: 2001
  ident: ref40/cit40
  publication-title: Cancer Res.
  contributor:
    fullname: Mendiratta S. K.
– ident: ref16/cit16
  doi: 10.1158/2326-6066.CIR-14-0177
– ident: ref21/cit21
  doi: 10.1016/j.biomaterials.2016.02.025
– ident: ref31/cit31
  doi: 10.1016/j.canlet.2008.10.021
– ident: ref13/cit13
  doi: 10.1016/j.ymthe.2017.04.026
– ident: ref34/cit34
  doi: 10.1038/nmat4644
SSID ssj0057876
Score 2.6603596
Snippet Exploring a rational delivery system of integrating chemotherapy with immunotherapy to broaden benefits of cancer immunochemotherapy is still under challenge....
SourceID proquest
crossref
pubmed
acs
SourceType Aggregation Database
Index Database
Publisher
StartPage 3123
SubjectTerms Animals
Cell Line, Tumor
Doxorubicin - pharmacology
Drug Delivery Systems
Immunotherapy
Liposomes
Mice
Mice, Inbred BALB C
Neoplasms
Title Immunogenic Hybrid Nanovesicles of Liposomes and Tumor-Derived Nanovesicles for Cancer Immunochemotherapy
URI http://dx.doi.org/10.1021/acsnano.0c09681
https://www.ncbi.nlm.nih.gov/pubmed/33470095
https://search.proquest.com/docview/2479421703
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bS8MwFA6iL_rg_TJvRNiDL5nLpe36OKZjivjiBnsraZvAkDVjbQfz13vSdlM3hj4GkhCSc_kO55wvCNV5S_LYdzXxhBZERMolkomQgE5SKZlUQhXVFm9ubyBehs7wmyx6NYPP6IOM0kQmptGMAG3bJusd5jV9-0tDu_O-MLpW7twygQwBMqCIJYvP2gbWDUXpbze0AVsWPqZ7UFZnpQU1oS0t-WjkWdiIPteJG_8-_iHar5AmbpeicYS2VHKM9n7wD56g0bPtDjEgQ6MI9-a2eQuDuTUzlRbVctho_DqamNSMYSCTGPfzsZmSR1g_UytzAf3ijpWhKS63BXEYV_1d81M06D71Oz1S_b1AJOc8I46jXC0oo8pRHi1qUCXXsYbYG7ReUsW08DwFYBBCcy-KwTT4QlERMx7CIp-foe3EJOoC4ZD7jgO2DPxlKFpCtzSPlW56ESAx3xeyhupwSUGlO2lQpMUZDaqbC6qbq6H7xYsFk5KJY_PUu8WLBqAtNgUiE2XyNGCWUB-isCavofPyqZebcS48izgv_3eeK7TLbH2LbW_n12g7m-bqBgBKFt4WovkFcarhFg
link.rule.ids 315,783,787,2774,27090,27938,27939,57072,57122
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dS8MwED-GPqgPfn_Mzwg--NLZNmmzPo6pbDoH4gTfStomMGTNWLfB_Ou9tN38QtDHhuRIL5e733EfAbigdUGTwFcWZ4pZLJa-JVwWWXgnHSFcIZnMsy26fuuZ3b14LxWw57UwuIkMKWV5EP-ju4BzhWOpSHXNjhF0m1rrZY_b3LxZ0Gg-zXWvET-_iCOjn4xgYtHM5wcBY43i7Ks1-gVi5qbmdgMeF5vMM0xea5NxVIvfvvVv_M9fbMJ6iTtJoxCULajIdBvWPnUj3IF-29SKaJSofkxaM1PKRVD56qnM8tw5ohXp9Ic60wP8EGlCepOBHlnXuH4qv81FLEyaRqJGpCCLwjEoq71mu_B8e9NrtqzyJQZLUErHludJXzHHdaQnuZNnpAqqEoWeOOoA4UhXMc4lQkN01HmcoKIImHRY4tIIFwV0D5ZSncoDIBENPA81G1rPiNWZqiuaSGXzGHFZEDBRhQtkUljepCzMg-SuE5acC0vOVeFyfnDhsOjL8fvU8_nBhnh3TEBEpFJPstA17fXRJ7NpFfaLE18Qo5Rxgz8P_7afM1hp9R46YafdvT-CVddkvpjCd3oMS-PRRJ4gdBlHp7m0vgMOtel_
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ba8IwFA5jg7E97H5x1wx82EudubS1j6IT3UQGU_CtpG0CMmzEVsH9-p20VTaHsD02JIc0OZfvcC5BqMxqgkWeoyyXK27xUDqWoDywQCaJEFRILrNsi57THvCXoT0sisJMLQxsIgFKSRbEN1I9iVTRYYA8wXgsYl2phgC8Tb31ju0Sat4tqDfel_rXsKCTx5LBVwZAsWro84uAsUhh8tMibYCZmblpHaLBaqNZlslHZZYGlfBzrYfjf__kCB0U-BPXc4Y5RlsyPkH737oSnqJRx9SMaOCsUYjbC1PShUEJ67lMshw6rBXujiY60WP4EHGE-7OxnlpNWD-Xa3MBE-OG4awpzskCk4yLqq_FGRq0nvuNtlW8yGAJxlhq2bZ0FCeUSFu6JMtMFUxFCjxy0AWCSKq460qAiOCwu2EECsPjkvCIsgAWeewcbcc6lpcIB8yzbdBwYEUDXuOqplgkVdUNAZ95HhclVIZD8guJSvwsWE6JX5ycX5xcCT0uL8-f5P05Nk99WF6uDzJkAiMilnqW-NS02QffrMpK6CK_9RUxxrhrcOjV3_Zzj3bfmi2_2-m9XqM9ahJgTP07u0Hb6XQmbwHBpMFdxrBflLjr-Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunogenic+Hybrid+Nanovesicles+of+Liposomes+and+Tumor-Derived+Nanovesicles+for+Cancer+Immunochemotherapy&rft.jtitle=ACS+nano&rft.au=Hu%2C+Mei&rft.au=Zhang%2C+Jiao&rft.au=Kong%2C+Li&rft.au=Yu%2C+Yulin&rft.date=2021-02-23&rft.issn=1936-0851&rft.eissn=1936-086X&rft.volume=15&rft.issue=2&rft.spage=3123&rft.epage=3138&rft_id=info:doi/10.1021%2Facsnano.0c09681&rft.externalDBID=n%2Fa&rft.externalDocID=10_1021_acsnano_0c09681
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1936-0851&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1936-0851&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1936-0851&client=summon